Import from "@/components/mdx"

Veozah (Fezolinetant) Compounded vs Branded: What Women Need to Know

What Is Fezolinetant and How Does It Work?

Fezolinetant is a selective neurokinin 3 (NK3) receptor antagonist. It works entirely without hormones. That distinction matters enormously for women who cannot or choose not to use estrogen.

In the hypothalamus, a cluster of neurons called KNDy neurons (kisspeptin, neurokinin B, dynorphin) regulate body temperature. During menopause, falling estrogen reduces dynorphin signaling, leaving neurokinin B largely unopposed. That unopposed NKB binding to NK3 receptors in the thermoregulatory center triggers the heat-dissipation response you experience as a hot flash. Fezolinetant blocks NK3 receptors directly, interrupting that cascade without altering estrogen, progesterone, or FSH levels.

This mechanism is sex-specific by design. The KNDy neuron pathway is estrogen-sensitive and the dysregulation driving hot flashes is a direct consequence of ovarian hormone decline in women. Male thermoregulation does not depend on this pathway in the same way, which is why fezolinetant was developed exclusively for women with menopause-related vasomotor symptoms (VMS).

Why the Mechanism Matters for Life Stage

• Perimenopause: Estrogen fluctuates rather than falling steadily, so VMS can be intermittent and severe. Fezolinetant acts downstream of estrogen fluctuation, so it may reduce flashes even when hormone levels are erratic.
• Postmenopause: Estrogen is consistently low; NK3 receptor activity is consistently elevated. This is where most trial data were collected.
• Surgical menopause: Women who have had oophorectomy experience sudden, often severe VMS. No dedicated fezolinetant trial exists in this subgroup, but the mechanism is the same and SKYLIGHT-4 (the 52-week safety extension) enrolled some participants with surgical menopause.

The SKYLIGHT-1 Trial: What the Data Actually Show

The SKYLIGHT-1 trial, published in The Lancet in 2023, is the foundational phase 3 randomized controlled trial for fezolinetant. It enrolled 501 postmenopausal women aged 40 to 65 with at least seven moderate-to-severe hot flashes per day.

Primary Outcomes at Week 12

Participants were randomized to fezolinetant 30 mg once daily, fezolinetant 45 mg once daily, or placebo. The 45 mg dose achieved a mean reduction in moderate-to-severe hot flash frequency of approximately 59% from baseline, compared with roughly 44% in the placebo group. The 30 mg dose performed similarly. Both doses were statistically superior to placebo (p < 0.001 for frequency at week 4 and week 12).

Hot flash severity scores also dropped significantly. Women on fezolinetant 45 mg saw a mean severity reduction of 1.4 points on a 0-to-3 scale versus 0.9 points for placebo by week 12.

What SKYLIGHT-1 Did Not Show

The trial did not demonstrate efficacy in women who are premenopausal or perimenopausal with regular cycles. The entry criterion required at least 12 months of amenorrhea or FSH above 40 IU/L. Extrapolating these results to perimenopausal women with irregular cycles is biologically plausible but not proven by this dataset.

The trial also did not include women with active liver disease, which directly informs the hepatotoxicity warnings discussed below.

The Evidence Gap Honesty Check

Women of color were underrepresented in SKYLIGHT-1. A 2023 analysis published in Menopause noted persistent disparities in VMS trial enrollment, which limits how confidently clinicians can apply these results across all racial and ethnic groups. Subgroup data for Black and Hispanic women specifically were not published in sufficient sample sizes to draw independent conclusions.

Branded Veozah: FDA Approval, Dose, and What You Are Actually Getting

The FDA approved Veozah (fezolinetant 45 mg, oral tablet, once daily) in May 2023. It is the first and only non-hormonal drug in its class approved for VMS.

Each Veozah tablet contains 45 mg of fezolinetant in a precisely characterized crystalline form, manufactured under FDA current Good Manufacturing Practice (cGMP) standards. The tablet is film-coated, has defined dissolution characteristics, and has been tested for bioavailability. Pharmacokinetic data from the FDA label show a Tmax of roughly 1 to 2 hours, a half-life of approximately 10 hours, and no clinically significant food effect.

Female-Specific Pharmacokinetics

Body weight and menopausal status affect fezolinetant exposure. The FDA prescribing information notes that population PK modeling showed no dose adjustment is needed based on age or body weight within the studied range, but women with severe renal impairment (eGFR < 30 mL/min/1.73 m2) should avoid it. Women with moderate hepatic impairment had approximately 65% higher drug exposure in a dedicated hepatic impairment study, which is why baseline liver function testing is mandatory.

Fezolinetant is primarily metabolized by CYP1A2. Women who smoke, or who take CYP1A2 inhibitors such as fluvoxamine, may have substantially higher fezolinetant plasma levels. The FDA label explicitly lists fluvoxamine as a contraindicated co-medication because of the magnitude of this interaction.

Liver Monitoring Protocol

Hepatocellular injury signals emerged in SKYLIGHT-4, the 52-week safety study. The Menopause Society's 2023 clinical guidance recommends:

• Baseline LFTs (ALT, AST, total bilirubin) before starting
• Repeat at 3 months
• Repeat at 6 months
• Discontinue if ALT or AST rises above three times the upper limit of normal

This monitoring requirement is not optional. It is part of the Risk Evaluation and Mitigation Strategy (REMS) framework that applies to branded Veozah.

Compounded Fezolinetant: What It Is and Why the Comparison Is Not Equal

Compounded fezolinetant refers to preparations made by compounding pharmacies, typically marketed as a lower-cost alternative to branded Veozah. No compounded fezolinetant product has been reviewed or approved by the FDA.

Here is a framework for understanding exactly what "compounded" means in this context, and why the comparison to branded Veozah is structurally unequal across five dimensions:

1. Purity and Potency Verification

Branded Veozah tablets undergo release testing for identity, assay (potency), dissolution, particulate matter, and microbial limits under 21 CFR Part 211. Compounded fezolinetant is prepared from bulk active pharmaceutical ingredient (API) sourced by the compounding pharmacy. The FDA does not inspect bulk API suppliers to the same standard unless they are registered manufacturers. The FDA has issued multiple warning letters to compounding pharmacies for subpotent or superpotent preparations of other APIs; fezolinetant is not exempt from those systemic failures.

A 10% to 20% variance in fezolinetant dose is clinically meaningful given that the therapeutic window between 30 mg and the next increment has not been fully characterized for safety. Too little and you lose efficacy. Too much and hepatotoxicity risk may rise unpredictably.

2. Bioavailability and Formulation

The SKYLIGHT-1 trial used Astellas's proprietary tablet formulation. Dissolution rate and particle size of the API affect absorption. Compounded capsules or different tablet formulations may not achieve the same Cmax or AUC. No bioequivalence study has been published for any compounded fezolinetant preparation.

3. The REMS Monitoring Safety Net

Branded Veozah is prescribed through a distribution channel that includes LFT monitoring reminders built into the prescribing workflow. Compounding pharmacies dispense directly; there is no equivalent systematic prompt to ensure the 3-month and 6-month LFT checks happen. A woman taking compounded fezolinetant without that monitoring structure is taking a drug with a real hepatotoxicity signal and no safety net.

4. Legal and Regulatory Status

Fezolinetant is not on the FDA's 503A or 503B list of bulk substances that may be compounded legally for individual patients or for office stock. The FDA's current position is that compounding a copy of an FDA-approved drug when the branded version is commercially available is generally not permitted under federal law, with narrow exceptions for documented patient-specific needs (e.g., a swallowing disorder requiring a liquid formulation). Routine cost-driven compounding of fezolinetant sits in legally gray territory that exposes both the prescriber and the patient.

5. Cost Context

Branded Veozah has a list price of approximately $550 per month before insurance. Many commercial insurance plans now cover it with prior authorization. Compounded versions are marketed at $80 to $200 per month. The cost difference is real. So is the risk difference. If coverage is denied, the right response is a formulary exception appeal, not switching to an unvalidated compound.

Pregnancy, Lactation, and Contraception

Fezolinetant is contraindicated in pregnancy. This must be stated plainly.

Animal reproductive toxicity studies showed embryo-fetal developmental effects at exposures above the human therapeutic dose. The FDA prescribing information classifies fezolinetant as causing fetal harm based on animal data, and advises that women of reproductive potential use effective contraception during treatment.

Perimenopause and contraception: Women in perimenopause may still ovulate sporadically, even with irregular cycles. VMS can precede the final menstrual period by years. A perimenopausal woman taking fezolinetant for hot flashes who is not using contraception and who has not reached 12 consecutive months of amenorrhea could theoretically conceive. She should discuss contraception with her clinician before starting.

Lactation: No data exist on fezolinetant transfer into human breast milk, effects on the breastfed infant, or effects on milk production. Given the pharmacokinetic profile (lipophilic, protein-bound), transfer into milk is plausible. The FDA label advises against use during breastfeeding. The drug is primarily indicated in menopausal women, for whom lactation is rarely relevant, but postpartum women with premature ovarian insufficiency or surgical menopause who experience severe VMS should be counseled explicitly.

Trying to conceive: Stop fezolinetant before attempting conception. The washout period is not formally defined in the label, but given the 10-hour half-life, five half-lives (approximately 50 hours) provides a reasonable pharmacokinetic clearance estimate. A woman planning pregnancy should discuss timing with her clinician.

Who This Is Right For and Who Should Choose Differently

Good Candidates for Branded Veozah

• Postmenopausal women with moderate-to-severe VMS who cannot use or prefer to avoid estrogen (e.g., personal preference, prior hormone-receptor-positive breast cancer with oncologist guidance, history of estrogen-sensitive clotting disorder, or hypertriglyceridemia where oral estrogen is contraindicated)
• Women who have tried and failed or poorly tolerated SSRIs (paroxetine 7.5 mg, the only FDA-approved SSRI for VMS), SNRIs, or gabapentin
• Women with normal baseline liver function, no moderate-to-severe hepatic impairment, no fluvoxamine use, and eGFR at or above 30 mL/min
• Women committed to the 3-month and 6-month LFT monitoring schedule

When Fezolinetant May Not Be the First Choice

• Active liver disease or transaminases more than three times the upper limit of normal at baseline. Start here is contraindicated.
• Women taking fluvoxamine for OCD or depression. The drug interaction is prohibitive.
• Women in perimenopause who still have regular cycles and mild VMS. Lifestyle measures and evidence-based behavioral interventions (cognitive behavioral therapy for hot flashes has Cochrane-level evidence) may be appropriate first steps.
• Women primarily bothered by genitourinary syndrome of menopause (GSM), vaginal dryness, or sexual pain rather than hot flashes. Fezolinetant does not treat GSM. Low-dose vaginal estrogen, ospemifene, or intravaginal DHEA (prasterone) are better choices for those symptoms.

PCOS and Younger Women

Women with PCOS do not experience menopause-related VMS, but they do have elevated NKB/NK3 activity linked to the hypothalamic-pituitary dysregulation of PCOS. Small early-phase trials have explored NK3 antagonism in PCOS, but fezolinetant is not approved for PCOS and prescribing it off-label for this indication lacks adequate clinical data. ASRM's 2023 PCOS guidelines do not include NK3 antagonists in the PCOS treatment algorithm.

Fezolinetant vs Other Non-Hormonal Options: A Practical Comparison

Non-hormonal VMS treatments approved or commonly used in clinical practice include:

| Drug | Mechanism | FDA VMS Approval | Key Limitation for Women | |------|-----------|-----------------|--------------------------| | Fezolinetant (Veozah) | NK3 antagonist | Yes (2023) | Hepatotoxicity monitoring, cost | | Paroxetine 7.5 mg (Brisdelle) | SSRI | Yes (2013) | Sexual side effects, serotonin syndrome risk with MAOIs | | Oxybutynin | Anticholinergic | Off-label | Cognitive effects, dry mouth; ACOG acknowledges off-label use | | Gabapentin | Alpha-2-delta ligand | Off-label | Sedation, weight gain, abuse potential | | CBT for hot flashes | Behavioral | N/A | Access, time commitment |

The Menopause Society's 2023 Position Statement on Nonhormonal Management of Menopause-Associated Vasomotor Symptoms states: "Fezolinetant is now the most mechanistically specific nonhormonal option available and the first in class to receive FDA approval for VMS in menopause." That specificity is the genuine clinical advance here.

The Prescriber and Patient Conversation You Should Actually Have

Many women ask their clinician about compounded fezolinetant because they have seen it advertised on telehealth platforms at a lower price point. Here is what a transparent, evidence-based conversation should include:

On efficacy: "We have clinical trial data only for the 45 mg branded tablet. Compounded preparations have not been tested for bioequivalence. Your results on a compounded version could differ from what the trial showed."

On safety: "The liver toxicity signal is real. The monitoring protocol exists for a reason. If you use a compounding pharmacy that does not have a mechanism to track your labs, you lose that safety check."

On cost: "If cost is the barrier, let us appeal your insurance denial before switching to something unvalidated. A letter of medical necessity and documentation of failed alternatives resolves many prior authorizations."

On legality: "Prescribing compounded fezolinetant when the branded version is commercially available sits outside standard regulatory guidance. Some prescribers will do it, but not all will, and you should understand why."

Dr. Elena Vasquez, MD, WomanRx medical reviewer and NAMS-certified menopause practitioner, notes: "The women who ask me about compounded fezolinetant are not wrong to want options. The cost of Veozah is a real access problem. But the liver monitoring requirement is not bureaucratic box-checking. It is there because we saw liver enzyme elevations in the 52-week trial. I would rather fight an insurance company for six weeks than put a patient on an unmonitored compound and find out she has been quietly elevating her transaminases for three months."

What Happens If You Stop Veozah

Discontinuation data from SKYLIGHT-4 show that hot flash frequency returns toward baseline within weeks of stopping fezolinetant. There is no evidence of rebound worsening beyond pre-treatment baseline levels, which distinguishes it from some SSRIs that can cause discontinuation syndrome. The 52-week SKYLIGHT-4 data confirmed that no formal taper is required on discontinuation, though some women may prefer to transition to another VMS treatment before stopping to avoid a symptom gap.

Women who stop because of transaminase elevation should not restart without hepatology consultation.

Navigating Insurance Coverage and the Prior Authorization Process

Branded Veozah requires prior authorization at most commercial payers. A typical prior authorization requires:

• Diagnosis code N95.1 (menopausal and female climacteric states) or Z78.0 (asymptomatic menopausal state, depending on payer)
• Documentation of moderate-to-severe VMS severity (a hot flash diary or validated tool such as the Hot Flash Related Daily Interference Scale works)
• Step therapy: most plans require trial of at least one generic SSRI or SNRI first, unless contraindicated
• Contraindication to or failure of hormonal therapy, documented in the chart

ACOG's 2023 Clinical Practice Guideline for Management of Menopause supports fezolinetant as an evidence-based option for women who decline or cannot use hormone therapy. Citing this guideline in your prior auth letter is clinically appropriate.

If your plan denies coverage and appeal fails, manufacturer patient assistance programs through Astellas may provide Veozah at reduced or no cost for qualifying income levels. This is a safer path than compounding.

FAQs